The Alternatives to PAIN Act requires Medicare prescription drug plans (PDPs) and Medicare Advantage prescription drug plans (MA–PDs) to reduce patient out‑of‑pocket obstacles for specified non‑opioid drugs used to treat acute or postoperative pain. The bill removes the Part D deductible for qualifying drugs, directs plans to put them on the lowest cost‑sharing tier, and bars step‑therapy protocols that force use of opioids before these alternatives as well as prior authorization requirements.
By targeting acute‑pain, non‑opioid medicines that lack a therapeutically equivalent product in the U.S. and that meet a price ceiling, the bill aims to accelerate clinician adoption of opioid‑sparing therapies while limiting eligibility to products the drafters view as clinically distinct and cost‑reasonable. That design creates immediate access gains for patients but shifts enrollment, utilization, and pricing incentives onto plan sponsors, manufacturers, and the Centers for Medicare & Medicaid Services (CMS).
At a Glance
What It Does
Requires Part D and MA–PD plans to waive the Part D deductible and place qualifying non‑opioid acute‑pain drugs on the lowest cost‑sharing tier; prohibits step therapy requiring use of an opioid and bans prior authorization for those drugs. The statutory changes take effect for plan years beginning on or after January 1, 2026.
Who It Affects
Medicare Part D sponsors (stand‑alone PDPs and MA–PDs), prescription benefit managers, manufacturers of non‑opioid acute‑pain drugs, and Medicare beneficiaries who receive postoperative or other acute pain treatment under Part D.
Why It Matters
The bill removes two of the most common access barriers—cost‑sharing and utilization management—for a narrowly defined class of non‑opioid pain drugs, potentially increasing their uptake and altering Part D formulary and pricing strategies while creating implementation and budgetary implications for plans and CMS.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends Medicare Part D’s statutory formulary and utilization management rules to make certain non‑opioid products easier for beneficiaries to get. Instead of leaving placement and prior authorization to plan discretion, the law directs plans to treat qualifying non‑opioid acute‑pain drugs as low‑burden items: beneficiaries do not owe the Part D deductible, co‑payments or coinsurance calculations must reflect placement on the plan’s lowest cost‑sharing tier, and plans cannot require prior approval or force patients to try an opioid first.
The aim is operational simplicity—faster patient access at the pharmacy counter—by eliminating two gatekeeping tools plans often use to manage specialty or newer products.
The bill sets a narrow eligibility screen for which drugs qualify. A product must have an FDA label for postoperative or other acute pain, must not act on opioid receptors, and must have no therapeutically equivalent alternative marketed in the U.S. In addition, the product’s wholesale acquisition cost for a monthly supply must be at or below a specialty‑tier monthly cost threshold that CMS will set.
Those conditions are designed to catch novel, clinically distinct alternatives while excluding high‑priced specialty agents and generic equivalents.For low‑income subsidy (LIS) beneficiaries the statute is conformed so that deductible and tiering treatment follow the new rules—meaning the same deductible waiver and lowest‑tier placement apply. The bill applies to both stand‑alone PDPs and MA–PD plans and explicitly defines step therapy and prior authorization for purposes of enforcement.
CMS will need to update Part D guidance and plan bid templates and to set the specialty‑tier cost threshold; plan sponsors will have to reconfigure formularies, benefit designs and utilization‑management systems before the 2026 plan year.Although the bill removes two common utilization controls (step therapy and prior authorization) for qualifying drugs, it leaves other management tools intact: plans can still negotiate price, exclude nonqualifying drugs, and apply other utilization limits not expressly prohibited (for example, quantity limits or medical necessity reviews outside the defined prior‑authorization construct). The law also gives CMS a central role—both in applying the Orange Book therapeutic‑equivalence test and in establishing the cost‑threshold—so administrative choices will shape which products ultimately benefit.
The Five Things You Need to Know
Effective date: the new Part D rules apply to plan years beginning on or after January 1, 2026.
Definition: a 'qualifying non‑opioid pain management drug' must be FDA‑labeled for postoperative or other acute pain, must not act on opioid receptors, and must have no therapeutically equivalent product marketed in the U.S. (per the FDA’s 'Orange Book').
Price cap: the drug’s wholesale acquisition cost (WAC) for a monthly supply must not exceed the monthly specialty‑tier cost threshold, which the Secretary of HHS will set and update.
Cost‑sharing and tiers: the bill eliminates the Part D deductible for qualifying drugs and requires plans to place them on the lowest cost‑sharing tier when calculating coinsurance or copayments (including for LIS beneficiaries).
Utilization management: PDPs and MA–PD plans may not impose step‑therapy that forces use of an opioid prior to a qualifying drug, and they may not subject qualifying drugs to prior authorization.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Declares the bill’s popular name: the 'Alternatives to Prevent Addiction In the Nation Act' or 'Alternatives to PAIN Act.' This is a standard heading that does not affect substance but signals congressional intent to frame the measure as opioid‑sparing policy.
Cost‑sharing waiver and lowest‑tier placement for qualifying non‑opioid drugs
Adds a new paragraph to the Part D benefit statute that waives the Part D deductible for covered drugs that meet the bill’s qualifying criteria and requires plans to treat those drugs as placed on the lowest cost‑sharing tier for purposes of calculating beneficiaries’ maximum coinsurance or other cost sharing. This is a direct beneficiary finance change: plans must reflect zero deductible exposure and must compute patient cost based on the plan’s lowest tier level rather than a specialty or higher tier. Operationally, plan benefit designs, point‑of‑sale pharmacy systems, and drug tiering tables will need updates.
Qualifying drug eligibility criteria
Specifies four gating conditions: (1) an FDA label indication for postoperative or other acute pain; (2) the product does not act on opioid receptors; (3) no therapeutically equivalent product exists in the U.S. as identified in the FDA’s 'Approved Drug Products with Therapeutic Equivalence Evaluations' (the Orange Book); and (4) the product’s WAC for a monthly supply does not exceed a specialty‑tier threshold set by the Secretary. The Orange Book and WAC references import established regulatory measures into the Part D context but require administrative choices—most notably CMS’s setting of the specialty‑tier cost threshold.
Treatment of low‑income subsidy beneficiaries
Modifies statutory language governing cost‑sharing protections for LIS beneficiaries so that the deductible waiver and lowest‑tier placement for qualifying drugs apply to low‑income enrollees as well. That alignment prevents a two‑tiered outcome where non‑LIS beneficiaries receive a deductible waiver while LIS rules inadvertently leave cost calculations unchanged; it obligates plan sponsors and CMS to harmonize LIS payment flows with the new rules.
Ban on step therapy requiring opioids and on prior authorization
Creates a statutory prohibition preventing a PDP or MA–PD plan from imposing step therapy that requires use of an opioid prior to coverage of a qualifying non‑opioid drug, and bars prior authorization for such drugs. The provision also defines 'step therapy' and 'prior authorization' for Part D purposes. The ban is narrow—limited to the defined qualifying drugs—but it removes two common utilization-management levers; plans will have to disable these rules for qualifying products while retaining other management strategies where permitted.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries with acute or postoperative pain — they face lower up‑front costs and fewer administrative hurdles for eligible non‑opioid options, improving access at the pharmacy and likely increasing prescriptions for these alternatives.
- Clinicians seeking opioid‑sparing regimens — fewer prior‑auth denials and no forced opioid trials reduce administrative friction and speed initiation of alternative therapies.
- Manufacturers of qualifying non‑opioid drugs without U.S. therapeutic equivalents — the rules remove two market access barriers (price sensitivity and utilization management) that can accelerate uptake of novel products priced under the CMS threshold.
Who Bears the Cost
- Part D plan sponsors (stand‑alone PDPs and MA–PDs) — plans absorb the programmatic impact of waived deductibles and must redesign formularies and utilization‑management rules, potentially increasing plan drug spending or shifting costs in negotiations with manufacturers and PBMs.
- Prescription benefit managers and pharmacies — PBMs must change prior‑authorization and step‑therapy logic and may face altered formulary placement negotiations; pharmacies will update point‑of‑sale systems to reflect deductible waivers and lowest‑tier pricing.
- CMS and HHS — the agencies must administer the Orange Book equivalence checks, establish and update the specialty‑tier monthly cost threshold, issue guidance and oversight, and handle appeals or compliance questions, adding regulatory workload without explicit funding in the statute.
Key Issues
The Core Tension
The central tension is between expanding immediate, low‑friction access to opioid‑sparing acute‑pain therapies and preserving plan tools to control costs and ensure clinically appropriate use: the bill removes price and administrative barriers for a narrowly defined set of drugs, but doing so shifts financial and programmatic risk to plans and to CMS’s discretionary choices about which drugs qualify.
The bill balances narrower eligibility against broader access tools, but that balance raises implementation and incentive questions. First, the Orange Book test plus a WAC ceiling limits qualifying drugs to products that are both clinically distinct and modestly priced; manufacturers can respond by pricing below the threshold to gain preferential access, which may compress margins and change launch strategies.
Second, while the bill prohibits step therapy that mandates an opioid first and prior authorization for qualifying drugs, it leaves other utilization controls intact; plans may rely more heavily on alternative tools such as exclusion from formularies, tighter negotiated net prices, or quantity limits to manage utilization, potentially blunting the access gains.
Operationally, CMS discretion matters. The Secretary will set the 'monthly specialty‑tier cost threshold' and apply Orange Book equivalence in borderline cases; those administrative choices determine the law’s reach.
The timing—implementation for 2026 plan years—gives plans limited runway to reconfigure systems. Finally, clinical scope is narrow: the bill targets acute and postoperative indications, not chronic pain, and requires an FDA label; off‑label prescribing (a common clinical practice) will not automatically benefit, which may create clinician confusion and variable patient outcomes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.